Pre-Test What Are The Latest Strategies For Relapsed CLL And What Is On The Horizon? Pre-Test The ALPINE Study Compared zanubrutinib 160 mg BID to ibrutinib 420 mg daily in relapsed CLL. Its findings for the primary endpoint include: Statistical significant improvement of investigator assessed ORR (CR+PR+PR-L) for zanubrutinib over ibrutinib Statistically significant improvement of investigator assessed ORR (CR+PR) for zanubrutinib over ibrutinib Statistical significant improvement of independent committee review assessed ORR (CR+PR) for zanubrutinib over ibrutinib Statistical significant improvement of investigator assessed PFS for zanubrutinib over ibrutinib Unsure BTK inhibitor dosing modifications are necessary when co-administered with agents that are metabolized by the _______ enzyme to avoid toxicity and ensure optimal efficacy and safety. modifications? OAT3 CYP3A CYP1A2 OATP1B1 Unsure The current dosing recommendation for ______ months of fixed-duration therapy with venetoclax plus rituximab was based on the MURANO trial in which undetectable MRD rates and longer PFS was observed compared to bendamustine plus rituximab? 6 12 24 36 Unsure 4. How confident are you in your ability to incorporate combination therapy with BTK and BCL-2 inhibitors for CLL/SLL into your clinical practice? Very confident Confident Somewhat confident Not very confident Not very confident
